Heck Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Heck Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9	Closed	-$230	–	682
2024 Q4	$230	Buy	+9	New	+$239	﹤0.01%	778

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Heck Capital Advisors's RPRX Position: Q1 2025 in Review

Heck Capital Advisors sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 9 shares — an estimated $230 sold.

Heck Capital Advisors first reported a position in RPRX in Q4 2024 and held it in 1 quarter. The position peaked at $230 in Q4 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

Heck Capital Advisors reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
Heck Capital Advisors sold 9 Royalty Pharma shares in Q1 2025, an estimated $230.
Heck Capital Advisors first reported a position in Royalty Pharma in Q4 2024 and held it in 1 quarter.
Heck Capital Advisors's Royalty Pharma position peaked at $230 in Q4 2024.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.